Abatacept
Treatment for Rheumatoid Arthritis
Typical Dosage: 125 mg once weekly (subcutaneous) or IV infusion based on weight
Effectiveness
78%
Safety Score
42%
Clinical Trials
139
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
42
DangerousModerateSafe
Treatment Details
Dosage Range
125 mg once weekly (subcutaneous) or IV infusion based on weight
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$55,000
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$57,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$125,000/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$95,833.33
Cost per Remission
$230,000
Comparison vs Methotrexate
Cost Difference
+$55,900/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Abatacept Outcomes
for Rheumatoid Arthritis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+60%
Remission Rate
+25%
Common Side Effects
Headache
+15%
Nausea
+10%
Upper respiratory tract infections
+18%
Infusion-related reactions (IV)
+8%
Serious infections
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Abatacept in Rheumatoid Arthritis
Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects
NCT06929039COMPLETEDPHASE1
300 participants
INTERVENTIONAL
Missisauga, Canada
Started: Jul 4, 2024
Abatacept With Methotrexate- Phase IIB
NCT00162266COMPLETEDPHASE2
524 participants
INTERVENTIONAL
Birmingham, United States +56 more
Started: Oct 1, 2000
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
NCT00989235COMPLETEDPHASE3
108 participants
INTERVENTIONAL
Started: Apr 1, 2007
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
NCT01439204COMPLETEDPHASE1
223 participants
INTERVENTIONAL
Omaha, United States
Started: Oct 1, 2011
A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
NCT03882008COMPLETEDPHASE4
25 participants
INTERVENTIONAL
Seattle, United States
Started: May 23, 2019
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
NCT01339481COMPLETED
26 participants
OBSERVATIONAL
Anniston, United States +6 more
Started: Feb 1, 2011
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
NCT00048581COMPLETEDPHASE3
738 participants
INTERVENTIONAL
Birmingham, United States +41 more
Started: Dec 1, 2002
Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
NCT01299961COMPLETEDPHASE3
25 participants
INTERVENTIONAL
Los Angeles, United States
Started: Mar 1, 2011
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
NCT01351480COMPLETEDPHASE3
34 participants
INTERVENTIONAL
Aventura, United States
Started: Jun 1, 2011
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
NCT00484289COMPLETEDPHASE3
217 participants
INTERVENTIONAL
Nagoya, Japan +38 more
Started: Dec 1, 2006
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
NCT01890473COMPLETEDPHASE1
356 participants
INTERVENTIONAL
Huntsville, United States +24 more
Started: Jul 1, 2013
Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa
NCT02598466COMPLETED
69 participants
OBSERVATIONAL
Started: Jul 1, 2015
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
NCT03714022COMPLETEDPHASE1
140 participants
INTERVENTIONAL
South Miami, United States +1 more
Started: Nov 9, 2018
Methotrexate-Inadequate Response Autoinjector Device Sub Study
NCT01844895COMPLETEDPHASE3
120 participants
INTERVENTIONAL
Started: Apr 1, 2013
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
NCT02037737COMPLETED
153 participants
OBSERVATIONAL
Started: Sep 30, 2016
Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg
NCT02600468COMPLETED
671 participants
OBSERVATIONAL
Started: Sep 1, 2013
Long Term Experience With Abatacept in Routine Clinical Practice
NCT02109666COMPLETED
2.36K participants
OBSERVATIONAL
Salzburg, Austria +12 more
Started: Mar 1, 2008
Showing 20 of 139 total trials